EyePoint, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EyePoint, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $701.0K | Sep 13, 2017 |
| FY2017 | Mar 31, 2017 | $590.0K | Sep 13, 2017 |
| FY2017 | Dec 31, 2016 | $5.97M | Sep 13, 2017 |
| FY2017 | Sep 30, 2016 | $277.0K | Sep 13, 2017 |
| FY2017 | Jun 30, 2016 | $304.0K | Sep 13, 2017 |
| FY2017 | Mar 31, 2016 | $324.0K | Sep 13, 2017 |
| FY2017 | Dec 31, 2015 | $526.0K | Sep 13, 2017 |
| FY2017 | Sep 30, 2015 | $466.0K | Sep 13, 2017 |
| FY2016 | Jun 30, 2015 | $409.0K | Sep 13, 2016 |
| FY2016 | Mar 31, 2015 | $328.0K | Sep 13, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.37M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $43.27M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $46.02M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $41.40M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $36.94M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $34.44M | Mar 14, 2022 |
| FY2019 | Dec 31, 2019 | $8.63M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $2.51M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $7.21M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $2.01M | Mar 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($231.96M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($130.87M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($70.80M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($102.25M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($58.42M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($45.39M) | Mar 14, 2022 |
| FY2019 | Dec 31, 2019 | ($10.41M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($15.65M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($11.50M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($19.24M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($243.43M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($145.85M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($75.07M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($99.64M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($55.28M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($37.29M) | Mar 14, 2022 |
| FY2019 | Dec 31, 2019 | ($8.99M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($14.06M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($10.17M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($14.65M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $221.04M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $132.93M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $64.66M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $49.64M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $28.50M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $17.42M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $15.37M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $10.41M | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $16.18M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $8.09M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($240.11M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($126.23M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.88M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($65.01M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($50.10M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($14.44M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($56.70M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($22.59M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | ($21.91M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2017 | ($20.49M) | Mar 16, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.28M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.05M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $3.48M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $2.15M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $156.0K | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $362.0K | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $213.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $132.0K | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $108.0K | Mar 16, 2020 |
| FY2019 | Jun 30, 2017 | $147.0K | Mar 16, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.00M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $418.47M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $355.18M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $180.36M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $263.37M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $91.72M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $72.97M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $78.17M | Mar 16, 2020 |
| FY2018 | Jun 30, 2018 | $71.67M | Sep 18, 2018 |
| FY2018 | Jun 30, 2017 | $18.68M | Sep 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.88M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $81.96M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $88.86M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $83.99M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $78.99M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $73.18M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $64.64M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $40.54M | Mar 16, 2020 |
| FY2018 | Jun 30, 2018 | $59.98M | Sep 18, 2018 |
| FY2018 | Jun 30, 2017 | $5.34M | Sep 18, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $306.11M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $336.50M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $266.32M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $96.37M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $184.38M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $18.54M | Mar 10, 2023 |
| FY2021 | Dec 31, 2019 | $8.33M | Mar 14, 2022 |
| FY2020 | Dec 31, 2018 | $37.63M | Mar 12, 2021 |
| FY2019 | Jun 30, 2018 | $11.69M | Mar 16, 2020 |
| FY2019 | Jun 30, 2017 | $13.34M | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.10B) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($873.02M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($742.15M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($671.35M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($569.10M) | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | ($510.68M) | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | ($465.29M) | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | ($408.49M) | Mar 16, 2020 |
| FY2018 | Jun 30, 2018 | ($363.99M) | Sep 18, 2018 |
| FY2018 | Jun 30, 2017 | ($310.82M) | Sep 18, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $101.82M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $99.70M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $281.26M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $95.63M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $178.59M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | $44.91M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | $22.21M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $45.26M | Mar 16, 2020 |
| FY2018 | Jun 30, 2018 | $38.78M | Sep 18, 2018 |
| FY2018 | Jun 30, 2017 | $16.90M | Sep 18, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $30.00M | Mar 10, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 10, 2023 |
| FY2017 | Jun 30, 2017 | 0 | Sep 13, 2017 |
| FY2017 | Jun 30, 2016 | 0 | Sep 13, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Sep 13, 2016 |
| FY2016 | Mar 31, 2015 | 0 | Sep 13, 2016 |
| FY2016 | Dec 31, 2014 | 0 | Sep 13, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 10, 2023 |
| FY2017 | Jun 30, 2017 | 0 | Sep 13, 2017 |
| FY2017 | Jun 30, 2016 | 0 | Sep 13, 2017 |
| FY2016 | Jun 30, 2015 | 0 | Sep 13, 2016 |
| FY2016 | Mar 31, 2015 | 0 | Sep 13, 2016 |
| FY2016 | Dec 31, 2014 | 0 | Sep 13, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 82.83M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 68.27M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 49.04M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 34.08M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 33.91M | Mar 10, 2023 |
| FY2021 | Dec 31, 2020 | 18.14M | Mar 14, 2022 |
| FY2020 | Dec 31, 2019 | 10.94M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 95.37M | Mar 16, 2020 |
| FY2018 | Jun 30, 2018 | 74.51M | Sep 18, 2018 |
| FY2018 | Jun 30, 2017 | 39.36M | Sep 18, 2018 |